![](/-/media/icons/2019/pharma/biomedtracker-icon.png?rev=fc7926a0385c4901b67c1887d9aac276)
Alexion buys Wilson Therapeutics
Executive Summary
Alexion Pharmaceuticals Inc. offered SEK232 ($27.84) per share to acquire Wilson Therapeutics AB, a Swedish biotech developing its sole candidate for the rare genetic condition Wilson disease. The deal is valued at SEK6.56bn (equity value SEK7.1bn on a fully diluted basis), and the share price represents a 62% premium to Wilson’s ten-day pre-announcement market average.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice